Mesentech Doses First Patients with Investigational Drug MES1022 to Accelerate Healing of Bone Fractures
VANCOUVER, BC — (BUSINESS WIRE) — Mesentech, a biotech company developing novel tissue-selective therapies to treat bone diseases, announced that it has dosed the first patients in its Phase 1… Read More




